

Quanterix™

Quanterix to Participate in Alzheimer's Association International Conference (AAIC) 2020

July 27, 2020

Company's ultra-sensitive Simoa® technology powers more than 50 posters and presentations on display during this year's virtual program; attendees can be among the first to experience Simoa p-tau181 assay for improved study of Alzheimer's disease and visit virtual exhibitor booth

BILLERICA, Mass.--(BUSINESS WIRE)--Jul. 27, 2020-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced its participation as a speaker and exhibitor at the [Alzheimer's Association International Conference \(AAIC\) 2020](#), being held virtually from July 27-31. The multi-day summit will feature more than 50 posters and presentations referencing the company's [Simoa® technology](#). In addition, Quanterix will present two posters and an oral presentation detailing the use of novel blood-based biomarkers to enhance the understanding of Alzheimer's disease (AD) and related dementias. An in-depth look at the company's latest multiplex neurology kit, [the Simoa® tau phosphorylated at threonine 181 \(p-tau181\) blood immunoassay](#), will also be available on-demand in the Product Theater Showcase.

"While we've recently broadened our R&D focus to address critical COVID-19 testing needs, supporting essential neurological research that could improve quality of life for the [50 million people living with dementia](#) globally remains a central part of our mission," said Kevin Hrusovsky, President, Chief Executive Officer and Chairman of Quanterix. "This year's AAIC may look different, but it continues to be an important forum for collaboration that is key to uncovering new treatments and preventative strategies for neurodegeneration. The overwhelming number of researchers sharing findings made possible with Simoa® is a true testament to the incredible potential of the high-sensitivity platform to support new discoveries integral to solving the mysteries of AD and one day eradicating the condition entirely."

At this year's event, Quanterix will showcase two posters detailing important advancements in assays to evaluate neuronal health. The research, titled "[Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood](#)" and "[An ultrasensitive immunoassay for detection of p-tau181 in blood](#)," further validates the use of Simoa® assays in the study of AD and serves as early evidence to support their clinical utility and use in drug development. The company will also be hosting a Product Theater Showcase, available on-demand for the duration of the event. Entitled, "Novel Simoa® p-tau181 Blood Immunoassay to Support Research, Therapeutics Development and Clinical Care of Alzheimer's Disease," the showcase offers a firsthand look at the Simoa® [p-tau181 Advantage assay](#) kit and preliminary data showing its utility as the premier marker for AD.

Attendees are also invited to view several oral presentations, live and on-demand, including [an oral presentation](#) at 8:30 a.m., ET on Tuesday, July 28 in the Session Chatroom. Hosted by [Professor Charlotte Teunissen](#) of [VU Medical Center in Amsterdam](#), the session will explore the effect of blood sample collection, handling and storage on novel blood-based biomarkers as evidenced by the first results of an in-depth biorepository assessment. Additionally, an [on-demand session from Alector](#) will highlight new findings from its INFRONT Phase 1b/2 clinical study which used Simoa® to investigate the effect of AL001, an investigational therapeutic, on biomarkers including neurofilament light chain (NfL) levels associated with frontotemporal dementia (FTD).

Considered to be among the largest and most influential international meetings dedicated to dementia research, AAIC convenes international investigators, clinicians, and care researchers to discuss the latest research aimed at improving global efforts to detect, treat and prevent Alzheimer's disease. As the company behind Simoa®, one of the most sensitive biomarker detection solutions on the market today, Quanterix has been instrumental in fueling critical advances in neurodegenerative research through the close study of neurological biomarkers. The Simoa® platform and its [menu of ready-to-use Simoa® assay kits](#) to detect minute concentrations of neurological markers, such as Neurofilament light (NfL), Tau, amyloid beta and GFAP in serum or plasma, have been featured in more than 500 neurology related publications. This is empowering diagnosis of neurodegenerative conditions years before symptoms, supporting more informed clinical care decisions, earlier entry into clinical trials and overall improved patient outcomes.

To learn more about Quanterix and its Simoa® technology, visit the virtual exhibit hall between 9 – 9:30 a.m., ET and 10:30-11 a.m., ET from July 27 – 30 or visit <https://www.quanterix.com/technology>.

For more details on Quanterix' participation at AAIC and the posters and presentations featuring Simoa®, click [here](#).

About Quanterix

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa®, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit <https://www.quanterix.com>.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as

"may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200727005107/en/): <https://www.businesswire.com/news/home/20200727005107/en/>

Media:

PAN Communications

Staci Didner

quanterix@pancomm.com

Investor Relations:

Stephen Hrusovsky

(774) 278-0496

shrusovsky@quanterix.com

Source: Quanterix Corporation